Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis

J Nucl Cardiol. 2023 Aug;30(4):1543-1553. doi: 10.1007/s12350-022-03171-6. Epub 2023 Jan 14.

Abstract

Background: Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and methotrexate has gained attention as steroid sparing agent although the supporting evidence is poor. This study compared prednisone monotherapy, methotrexate monotherapy or a combination of both, in the reduction of myocardial Fluorine-18 fluorodeoxyglucose (FDG) uptake and clinical stabilization of CS patients.

Methods and results: In this retrospective cohort study, 61 newly diagnosed and treatment naïve CS patients commenced treatment with prednisone (N = 21), methotrexate (N = 30) or prednisone and methotrexate (N = 10) between January 2010 and December 2017. Primary outcome was metabolic response on FDG PET/CT and secondary outcomes were treatment patterns, major adverse cardiovascular events, left ventricular ejection fraction, biomarkers and side effects. At a median treatment duration of 6.2 [5.7-7.2] months, 71.4% of patients were FDG PET/CT responders, and the overall myocardial maximum standardized uptake value decreased from 6.9 [5.0-10.1] to 3.4 [2.1-4.7] (P < 0.001), with no significant differences between treatment groups. During 24 months of follow-up, 7 patients (33.3%; prednisone), 6 patients (20.0%; methotrexate) and 1 patient (10.0%; combination group) experienced at least one major adverse cardiovascular event (P = 0.292). Left ventricular ejection fraction was preserved in all treatment groups.

Conclusions: Significant suppression of cardiac FDG uptake occurred in CS patients after 6 months of prednisone, methotrexate or combination therapy. There were no significant differences in clinical outcomes during follow-up. These results warrant further investigation of methotrexate treatment in CS patients.

Keywords: Cardiac sarcoidosis; FDG PET/CT; immunosuppressants; methotrexate; prednisone.

MeSH terms

  • Cardiomyopathies* / complications
  • Cardiomyopathies* / diagnostic imaging
  • Cardiomyopathies* / drug therapy
  • Fluorodeoxyglucose F18 / therapeutic use
  • Humans
  • Methotrexate / therapeutic use
  • Myocarditis* / complications
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography / methods
  • Prednisone / therapeutic use
  • Radiopharmaceuticals / therapeutic use
  • Retrospective Studies
  • Sarcoidosis* / complications
  • Sarcoidosis* / diagnostic imaging
  • Sarcoidosis* / drug therapy
  • Stroke Volume
  • Ventricular Function, Left

Substances

  • Prednisone
  • Fluorodeoxyglucose F18
  • Methotrexate
  • Radiopharmaceuticals